Results 31 to 40 of about 5,892 (166)

Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients.

, 2022
BACKGROUND Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of Tolvaptan treatment on mineral metabolism and bone mineral density is unknown.
Nasser A Dhayat, Bargagli, Matteo, Daniel G Fuster, Anderegg, Manuel A, Faller, Nicolas, Fuster, Daniel G, Matteo Bargagli, Manuel A Anderegg, Vogt, Bruno, Uyen Huynh-Do, Ferraro, Pietro Manuel, Huynh-Do, Uyen, Nicolas Faller, Pietro Manuel Ferraro, Dhayat, Nasser A, Bruno Vogt, Andri Vetsch, Vetsch, Andri   +17 more
core   +1 more source

Tolvaptan Attenuates Left Ventricular Fibrosis After Acute Myocardial Infarction in Rats

Journal of Pharmacological Sciences, 2013
Tolvaptan, a non-peptide V2-receptor antagonist, is a newly developed diuretic agent. Recently, we reported that tolvaptan has diuretic as well as anti-inflammatory and anti-fibrotic actions in chronic heart failure.
Takanori Yamazaki, Yasuhiro Nakamura, Masayuki Shiota, Mayuko Osada-Oka, Hiroyuki Fujiki, Akihisa Hanatani, Kenei Shimada, Katsuyuki Miura, Minoru Yoshiyama, Hiroshi Iwao, Yasukatsu Izumi   +10 more
doaj   +1 more source

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

BMC Nephrology, 2017
Background Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD ...
Safa Al Therwani, My Emma Sofie Malmberg, Jeppe Bakkestroem Rosenbaek, Jesper Noergaard Bech, Erling Bjerregaard Pedersen   +4 more
doaj   +1 more source

Analysis of dose effect of tolvaptan on polycystic liver disease.

, 2022
To assess the dose effect of tolvaptan on the change in annual growth rate of total liver volume (TLV), the original tolvaptan group were stratified by daily dose of tolvaptan, less than 30mg, 60mg, 90mg, and mg. However, we could not find the any trends
Akinari Sekine (4357189), Eiko Hasegawa (848440), Naoki Sawa (848442), Hiroki Mizuno (560647), Tatsuya Suwabe (848436), Masayuki Yamanouchi (848441), Junichi Hoshino (848432), Daisuke Ikuma (12102061), Yoshifumi Ubara (848444)   +8 more
core   +1 more source

Real-life use of tolvaptan in ADPKD: a retrospective analysis of a large Canadian cohort

Scientific Reports, 2023
Tolvaptan is the first disease-modifying drug proven to slow eGFR decline in high-risk patients with ADPKD. However, barriers from the patient perspective to its use in real-life settings have not been systemically examined in a large cohort.
Luca Calvaruso, Kevin Yau, Pedram Akbari, Fatemah Nasri, Saima Khowaja, Bill Wang, Amirreza Haghighi, Korosh Khalili, York Pei   +8 more
doaj   +1 more source

Tolvaptan- A nd Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury

, 2020
Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients.
Hammond, S, Jaruthamsophon, K, Mosedale, M, Roth, S, Gibson, A, Naisbitt, DJ   +5 more
core   +1 more source

Otomozal dominant polikistik böbrek hastalığında tolvaptan kullanımı: Tek merkez deneyimi

, 2023
Aim: Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease that progresses to end-stage renal disease (ESRD). Tolvaptan is a disease-modifying agent that slows cyst growth and kidney disease progression in ADPKD. In this study,
Cebrail KARACA, Karaca, Cebrail, Dincer, Mevlüt Tamer, Mevlut Tamer DİNCER   +3 more
core   +1 more source

Equivalent Efficacy and Decreased Rate of Overcorrection in Patients With Syndrome of Inappropriate Secretion of Antidiuretic Hormone Given Very Low-Dose Tolvaptan

Kidney Medicine, 2020
Rationale & Objective: Euvolemic hyponatremia often occurs due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Vasopressin 2 receptor antagonists may be used to treat SIADH.
Ramy M. Hanna, Juan Carlos Velez, Anjay Rastogi, Minhtri K. Nguyen, Mohammad K. Kamgar, Kyaw Moe, Farid Arman, Huma Hasnain, Niloofar Nobakht, Umut Selamet, Ira Kurtz   +10 more
doaj   +1 more source

Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan

Therapeutic Advances in Cardiovascular Disease, 2019
Background: Although tolvaptan, an electrolyte-free water diuretic for congestive heart failure (HF), is reported to have no effect on long-term mortality or HF-related morbidity, there may exist some subgroups of patients who may receive beneficial ...
Kensuke Fujioka, Sumio Mizuno, Taro Ichise, Takao Matsui, Hiroaki Hirase, Masato Yamaguchi, Takahiko Aoyama, Masakazu Yamagishi, Noboru Fujino, Masa-aki Kawashiri, Kenshi Hayashi   +10 more
doaj   +1 more source

A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease

BMC Nephrology, 2022
Background Tolvaptan was approved in the United States in 2018 for patients with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression as assessed in a 3-year phase 3 clinical trial (TEMPO 3:4).
Gregory Mader, Deirdre Mladsi, Myrlene Sanon, Molly Purser, Christine L. Barnett, Dorothee Oberdhan, Terry Watnick, Stephen Seliger   +7 more
doaj   +1 more source